Related Experiment Videos
[Phase II study of mitoxantrone for hematologic malignancies]
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|November 1, 1983
Summary
Mitoxantrone (MIT) showed partial response in some lymphoma patients refractory to chemotherapy. While not effective in acute leukemia, it caused cytoreduction, with myelosuppression as the main toxicity.
Area of Science:
- Oncology
- Pharmacology
Context:
- Hematologic malignancies often become refractory to standard combination chemotherapy, including anthracyclines.
- There is a need for alternative therapeutic agents in patients with relapsed or refractory hematologic cancers.
Purpose:
- To evaluate the efficacy and toxicity of mitoxantrone (MIT) in patients with hematologic malignancies refractory to prior chemotherapy.
Summary:
- A phase II study administered mitoxantrone to 21 patients with refractory hematologic malignancies (14 lymphoma, 7 acute leukemia).
- Four lymphoma patients (2 Hodgkin's disease, 2 non-Hodgkin's lymphoma) achieved partial response.
- No definite response was observed in acute leukemia patients, though 2 showed marked cytoreduction.
- Myelosuppression was the primary toxicity, but no life-threatening adverse events were reported.
Impact:
- Mitoxantrone demonstrates potential activity in specific subgroups of refractory lymphoma patients.
- The study highlights the need for further investigation into mitoxantrone's role in hematologic oncology.
- Understanding toxicity profiles, particularly myelosuppression, is crucial for clinical application.